Vicapsys Life Sciences, Inc. (VICP)
USD 1.77
(39.37%)
USD 1.77
(39.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.04 Million USD | -283.45% |
| 2022 | -984.79 Thousand USD | 32.67% |
| 2021 | -305.54 Thousand USD | 44.78% |
| 2020 | -734.42 Thousand USD | 26.75% |
| 2019 | -1 Million USD | 13.4% |
| 2018 | -1.15 Million USD | 62.11% |
| 2017 | -3.05 Million USD | 0.0% |
| 2009 | -1.22 Million USD | 44.86% |
| 2008 | -2.24 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -585.49 Thousand USD | -154.14% |
| 2023 Q1 | -211.27 Thousand USD | -46.16% |
| 2023 Q3 | -230.38 Thousand USD | -69.78% |
| 2023 Q2 | -135.69 Thousand USD | 35.77% |
| 2022 FY | - USD | 32.67% |
| 2022 Q2 | -172.23 Thousand USD | -8.17% |
| 2022 Q3 | -137.25 Thousand USD | 20.31% |
| 2022 Q4 | -144.55 Thousand USD | -5.32% |
| 2022 Q1 | -159.22 Thousand USD | -65.87% |
| 2021 Q2 | -64.24 Thousand USD | 54.74% |
| 2021 FY | - USD | 44.78% |
| 2021 Q4 | -95.99 Thousand USD | 7.12% |
| 2021 Q3 | -103.35 Thousand USD | -60.9% |
| 2021 Q1 | -141.94 Thousand USD | -95.22% |
| 2020 Q3 | -81.35 Thousand USD | 63.64% |
| 2020 Q2 | -223.75 Thousand USD | 37.25% |
| 2020 FY | - USD | 26.75% |
| 2020 Q1 | -356.59 Thousand USD | -45.98% |
| 2020 Q4 | -72.71 Thousand USD | 10.63% |
| 2019 Q2 | -143.43 Thousand USD | 7.92% |
| 2019 FY | - USD | 13.4% |
| 2019 Q4 | -244.27 Thousand USD | 46.8% |
| 2019 Q3 | -459.12 Thousand USD | -220.08% |
| 2019 Q1 | -155.77 Thousand USD | -98.43% |
| 2018 Q4 | -78.5 Thousand USD | 0.0% |
| 2018 FY | - USD | 62.11% |
| 2017 FY | - USD | 0.0% |
| 2010 Q1 | -595.05 Thousand USD | -39899.95% |
| 2010 Q2 | -1.33 Million USD | -124.08% |
| 2009 FY | - USD | 44.86% |
| 2009 Q4 | -1487.63 USD | 0.0% |
| 2009 Q2 | -457.3 Thousand USD | -78.4% |
| 2009 Q1 | -256.33 Thousand USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -134.07% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 96.452% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 99.082% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 93.357% |
| Better Therapeutics, Inc. | -38.26 Million USD | 97.264% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 97.264% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 94.147% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 96.896% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 96.863% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 99.015% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -14.615% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 96.777% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 97.758% |
| Innovation1 Biotech Inc. | -5.68 Million USD | 81.579% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 93.577% |
| Molecular Templates, Inc. | 1.43 Million USD | 173.215% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 92.454% |
| NexImmune, Inc. | -28.16 Million USD | 96.283% |
| Orgenesis Inc. | -60.71 Million USD | 98.276% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 97.959% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -1326.09% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 93.515% |
| Scopus BioPharma Inc. | -11.71 Million USD | 91.062% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 99.806% |
| Statera Biopharma, Inc. | 38.93 Million USD | 102.689% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 84.791% |
| Trevena, Inc. | -35.28 Million USD | 97.033% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -1767.902% |
| Vaccinex, Inc. | -19.74 Million USD | 94.698% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 97.766% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 85.585% |